Previous Close | 3.5800 |
Open | 3.5800 |
Bid | 3.6800 x 2200 |
Ask | 3.7500 x 1000 |
Day's Range | 3.5800 - 3.7700 |
52 Week Range | 2.0200 - 7.2000 |
Volume | |
Avg. Volume | 1,144,232 |
Market Cap | 294.163M |
Beta (5Y Monthly) | 1.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2022, after the market close on Wednesday, July 27, 2022.